UroGen Pharma's (URGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research note released on Wednesday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other research firms have also recently weighed in on URGN. EF Hutton Acquisition Co. I raised UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Oppenheimer reiterated an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma presently has an average rating of "Buy" and a consensus price target of $43.70.

UroGen Pharma Trading Up 4.6 %

URGN traded up $0.46 during trading on Wednesday, hitting $10.39. The company's stock had a trading volume of 662,751 shares, compared to its average volume of 503,672. UroGen Pharma has a twelve month low of $9.78 and a twelve month high of $20.70. The stock has a market cap of $243.69 million, a PE ratio of -3.30 and a beta of 1.09. The firm's 50 day moving average price is $11.50 and its 200-day moving average price is $13.21. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to analysts' expectations of $24.22 million. During the same quarter in the prior year, the company earned ($0.68) EPS. On average, analysts expect that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Marshall Wace LLP bought a new position in UroGen Pharma during the second quarter worth about $719,000. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company's stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the period. Barclays PLC lifted its holdings in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after purchasing an additional 48,040 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company's stock worth $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Finally, Wesbanco Bank Inc. bought a new stake in UroGen Pharma in the 3rd quarter valued at $945,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.